SEC Form 4 · accession 0001140361-16-091061
CytomX Therapeutics, Inc. · CTMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Rachel Humphrey
Officer — Chief Medical Officer
Period of report
Dec 28, 2016
Accepted (ET)
Dec 29, 2016 · 3:52 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001501989
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 28, 2016 | M | 15,117 | $6.6147 | A | 15,117 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $6.6147 | Dec 28, 2016 | M | 15,117 | D | — | Aug 27, 2025 | Common Stock | 15,117 | 278,097 | D |
Explanation of responses
- F1This option vests 25% on August 28, 2016, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, with each additional installment vesting on the last day of the month, except the final installment, which shall vest on August 28, 2019.